MDS & Myeloproliferative NeoplasmsTopic Compilations MDS & Myeloproliferative Neoplasms Wednesday, January 5, 2000 A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms. IPSS That Incorporates Gene Mutations Offers Better Risk Stratification for MDS An updated International Prognosis Scoring System (IPSS) for myelodysplastic syndromes (MDS) that considers gene mutations (IPSS-M) led to improved discrimination compared with the revised... Germline Variants in DNA Repair Pathway Genes May Trigger Familial MPNs Germline variants in DNA repair pathway genes, such as BRCA1/2, may trigger familial myeloproliferative neoplasms (MPNs), suggesting these variants should be incorporated in diagnostic... New Prognostic Model Outperforms Established Predictive Models in MDS In a study published in the Journal of Clinical Oncology, researchers reported that a newly developed personalized prediction model comprising clinical and genomic data... Reduced-Intensity Conditioning Transplant Superior to Continuous 5-Azacitidine in Older Patients With MDS In older patients with advanced myelodysplastic syndromes (MDS), reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) improved event-free survival (EFS) compared with continuous 5-azacitidine therapy.... Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according... Avapritinib Approved for Advanced Systemic Mastocytosis The FDA has approved avapritinib for the treatment of adult patients with advanced systemic mastocytosis (SM), SM with an associated hematologic neoplasm, and mast... Exploring Venetoclax Plus Azacitidine in CMML and MPNs The combination of the BCL2 inhibitor venetoclax and the hypomethylating agent azacitidine has been established as a standard of care for patients with acute... Survival Outcomes After HLA-Haploidentical Relative Versus Matched Unrelated Donor Transplant in Acute Leukemias and... In patients with acute leukemias or myelodysplastic syndromes (MDS), those who underwent haploidentical relative hematopoietic cell transplantation (haploHCT) had higher rates of grade 3-4... Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with IDH2-mutated, high-risk myelodysplastic syndromes (MDS), according to results from... PATHFINDER: Avapritinib Induces Rapid Responses in Advanced Systemic Mastocytosis Three-quarters of patients with advanced systemic mastocytosis (SM) responded to treatment with the oral KIT D816V inhibitor avapritinib, according to interim results from the...